Co-Diagnostics, Inc.

CODX

NASDAQHealthcareBiotechnology

在 GoAI 中打開

前收盤價

US$1.21

+US$0.06 · +5.22%

8月21日下午4:00 ET

盤中時間採用ET。市場資料可能有所延遲。

GoAI 研究快照

簡明呈現最新可用的模型資訊。

2026年7月10日

31/ 100

GoAI評分

Sell

Trim exposure — unfavorable risk-reward

估值

Fair Value

動能

Strong Down

情緒

Mixed

風險韌性

Extreme Risk

完整 GoAI 研究

繼續查看更深入的依據、催化因素和風險。

看完整研究

人工智慧產生的上下文僅供參考，並非投資建議。

公司概況

公司網站

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.

產業: Biotechnology
部門: Healthcare
總部: US
執行長: Dwight Egan
上市以來: 2017年7月12日
僱員: 115

市場位置

日內區間

目前US$1.21，

US$1.18US$1.23

52週區間

目前US$1.21，

US$0.94US$46.50

開盤價: US$1.18
前收盤價: US$1.15
成交量: 29.33萬; 0.07× 平均值
平均成交量: 411.79萬; 日均成交量
市值: 135.07萬 USD
貝塔: 2.88; 市場參考 1
50天平均值: US$2.3529; 低於平均水平-48.57%
200天平均值: US$4.1466; 低於平均水平-70.82%

財務數據

財務快照

估值與收益率

本益比（TTM）: -0.05×
股價淨值比（TTM）: 0.41×
股價營收比（TTM）: 1.87×
股息率: 0.00%

獲利能力和效率

毛利率: 8.07%
營業利益率: -4170.14%
淨利潤率: -6523.04%

財務健康

負債權益比: 0.14×
奧特曼 Z 分數: -17.32
皮奧特羅斯基 F 分數: 2 共 9 個

分析師評級

第三方分析師預期可能變動，並非 GoAI 建議。

分析師目標價

平均目標

US$180

上漲空間 14776.03%

過去 12 個月12個月預測最高：US$180平均的：US$180最低：US$180

近期分析師行動

2 機構

CODX 訊息

prnewswire.com2026年8月18日

Co-Diagnostics Participates in Medical Devices and Innovations Roundtable Media Event

Company Chief Commercialization Officer represented Co-Dx in an event featuring other industry stakeholders held on August 13 in Salt Lake City, UT SALT LAKE CITY, Aug. 18, 2026 /PRNewswire/ -- Co-Diagnostics, Inc.…

閱讀原始碼

seekingalpha.com2026年8月13日

Co-Diagnostics, Inc. (CODX) Q2 2026 Earnings Call Transcript

閱讀原始碼

prnewswire.com2026年8月13日

Co-Diagnostics Reports Second Quarter 2026 Financial Results

Advancing Commercialization Through FDA Submission, Global Clinical Progress and Manufacturing Expansion Strengthening Integrated Co-Dx PCR Platform Through Scientific Innovation, Cloud Connectivity and AI-Enabled…

閱讀原始碼

prnewswire.com2026年8月6日

Co-Diagnostics Submits FDA 510(k) Premarket Notification for Upper Respiratory Point-of-Care Test

Submission includes a concurrent CLIA Waiver by Application for use of the test on the Co-Dx PCR Pro ® instrument in decentralized point-of-care settings SALT LAKE CITY, Aug. 6, 2026 /PRNewswire/ -- Co-Diagnostics, Inc.…

閱讀原始碼

prnewswire.com2026年7月30日

Co-Diagnostics Announces Second Quarter 2026 Earnings Release Date and Webcast

SALT LAKE CITY, July 30, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic…

閱讀原始碼

prnewswire.com2026年7月28日

Co-Diagnostics Joint Venture CoSara Provides Ebola Test Kits for Analytical Studies

Company also completes proof of concept for the first blood-borne test for Ebola on Co-Dx PCR Pro ® instrument SALT LAKE CITY, July 28, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"),…

閱讀原始碼